Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 4Recruiting 2Completed 2Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Sarcoma 1Lung Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma 1Breast Neoplasms 1

Interventions

Leucovorin 5Gemcitabine 5Fluorouracil 5Cisplatin 5durvalumab 3Oxaliplatin 3Capecitabine 3pembrolizumab 2lenvatinib 2S 1 (combination) 2Irinotecan 2Folfox protocol 2zimberelimab 1tocilizumab 1tislelizumab 1surufatinib 1regorafenib 1pemigatinib 1neratinib 1fludarabine 1donafenib 1dehydroftorafur 1Surgical Procedures, Operative 1Radiotherapy 1Proton Therapy 1Platinum 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Immune Checkpoint Inhibitors 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Cholangiocarcinoma × pemigatinib × Clear all
NCT06530823 2024-07-31

Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma

Eastern Hepatobiliary Surgery Hospital

Phase 2 Not yet recruiting
38 enrolled
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡